Skip to main content
Fig. 1 | Molecular Medicine

Fig. 1

From: Pan-cancer analysis reveals RIPK2 predicts prognosis and promotes immune therapy resistance via triggering cytotoxic T lymphocytes dysfunction

Fig. 1

RIPK2 expression in various cancers and different pathological stages. A The expression of RIPK2 is compared between tumor tissue and normal tissue using TIMER 2.0 (*p < 0.05, **p < 0.01, and ***p < 0.001). B Expression status of RIPK2 in different cancer types from TCGA and GTEx data (*p < 0.05, **p < 0.01, and ***p < 0.001). C Based on the TCGA data, RIPK2 expression levels of different types of cancer (KICH, KIRC, KIRP, LUAD, LUSC, THCA) were analyzed by different pathological stages (stage I, stage II, stage III, and stage IV). D Different RIPK2 expression levels between normal tissue, tumor tissue, and metastatic tissue in PRAD, BRCA, KIRC, ESCA, and PAAD. E Expression of RIPK2 protein in stomach normal tissue, stomach adenocarcinoma, tonsil normal tissue, and tonsil malignant lymphoma from HPA database. F Immunofluorescence staining of RIPK2 protein in the normal tissue and tumor tissue in KIRC

Back to article page